February 9, 2026 – Hualan announced that its wholly-owned subsidiary has partnered with an elite technical team distinguished for its achievements in AI-powered biomedicine to establish a new Joint Venture (JV).The team is led by Mr. Kaixian Yu, former CTO of U.S.-based Insilicom LLC, and Professor Jun Liu, a member of the U.S. National Academy of Sciences. The JV will focus on Knowledge Graph-powered Drug Repurposing and Pharmacovigilance services. This initiative aims to explore deep application scenarios for AI in drug R&D and safety management, marking a pivotal step in Hualan's transformation into an AI-driven pharmaceutical technology leader.

Opening New "Blue Oceans" with Knowledge Graph Technology

The JV will prioritize Drug Repurposing, a global trend in R&D that identifies new therapeutic indications for existing drugs. By leveraging established safety data, this strategy significantly shortens development cycles, reduces costs, and improves success rates, offering immense scientific and commercial value.The core of this strategy lies in the intelligent association and deep mining of massive biomedical data. Knowledge Graph technology is the essential tool for building structured semantic knowledge bases. By systematically integrating multi-dimensional data—including drugs, diseases, genes, and proteins—into a clear relational network, it provides a robust and reliable AI engine for precise drug repurposing.

Simultaneously, the JV will focus on the high-growth field of Pharmacovigilance. By constructing specialized safety knowledge graphs, the company will enable real-time monitoring and intelligent analysis of adverse drug reaction signals. This allows pharmaceutical enterprises and medical institutions to optimize risk warnings and clinical decision-making, enhancing the overall efficiency of drug safety management.

Integrating Globally Validated Technical Excellence

As the core leader of this collaboration, Mr. Kaixian Yu brings extensive academic depth and industrial experience. During his tenure as CTO of Insilicom LLC, he spearheaded the development of industry-leading AI pharmaceutical platforms and knowledge graph systems, playing a crucial role in product innovation and commercialization.

The technical strength of Mr. Yu and his team has been validated through multiple global competitions and stable partnerships with top-tier international pharmaceutical companies. Their joining injects globally proven, cutting-edge technical DNA directly into Hualan, ensuring a high-altitude and forward-looking layout in the AI-pharma sector.

A Strategic Vision for Future R&D

The establishment of this Joint Venture is a key strategic implementation for Hualan as it actively embraces technological innovation and new paradigms in medicine. Through this partnership, Hualan aims to drive the deep integration of AI and the pharmaceutical industry, contributing to global R&D efficiency and the safeguarding of patient health.